16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
October 2010 in “eCommons (Cornell University)” Cutaneous epitheliotropic lymphoma in dogs is often misdiagnosed but can be treated with chemotherapy and alternative therapies.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
1 citations
,
April 2025 in “Skin Health and Disease” Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” 13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
6 citations
,
November 1999 in “Mycoses” A man in Japan got better from a scalp fungal infection using terbinafine.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
January 2024 in “Acta dermato-venereologica”
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
February 2026 in “JAAD International”
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia”
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
22 citations
,
September 2014 in “Hormones” Metformin may help treat neuroendocrine tumors.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
Suppressing ODC activity reduces tumor growth in hair follicles.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
10 citations
,
December 2008 in “Molecular Carcinogenesis” The PML protein helps prevent skin cancer in mice.
September 2017 in “Journal of Investigative Dermatology” LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.